7 results about "Drug specific IgE" patented technology

The invention discloses a polypeptide oligonucleotide conjugate and application thereof. The polypeptide oligonucleotide conjugate comprises (1) a polypeptide combined with an LRP2 receptor and (2) one or two oligonucleotide drugs used for regulating and controlling kidney target gene expression. The conjugate uses an LRP2 targeting peptide to specifically deliver a siRNA drug to the kidney.

This invention provides a bispecific antibody targeting tissue factors, an antibody-drug conjugate (ADC), its preparation method, and its application, belonging to the field of biopharmaceutical preparation technology. The bispecific antibody provided by this invention can efficiently target tissue factors in tumor cells, exhibiting advantages such as strong affinity and high endocytosis efficiency. This invention also provides an ADC, which, under the action of the bispecific antibody, specifically binds to tumor surface antigens and is internalized into tumor cells, achieving precise drug delivery for antitumor drugs. The ADC provided by this invention exhibits good tumor-suppressing effects in both cell and animal models, and is non-toxic and harmless to animals, demonstrating excellent potential for cancer treatment.

The present invention relates to the technical field of medicine, and relates in particular to a molecule having a targeting function. The molecule having a targeting function can specifically deliver a drug to a specific cell, which facilitates precise programming of a specific cell in the body, a therapeutic effect of the drug is produced, and consequently drug dosage and side effects are greatly reduced, and the effect of precise treatment to cells in the body is achieved.

This invention relates to the field of pharmaceutical chemistry, specifically to a Devimistat derivative with mitochondrial targeting function, its preparation method, and its application in antitumor drugs. This derivative covalently couples the mitochondrial-attractant 3-aminopropyl(triphenyl)phosphine bromide (TPP) group to the antitumor active molecule Devimistat, utilizing the affinity of the TPP cation for the mitochondrial transmembrane potential to drive the drug's specific accumulation in the mitochondrial matrix. While retaining the original drug's interference with the tricarboxylic acid cycle and inhibition of PDH and KGDH complex activity, this derivative significantly increases the effective drug concentration within tumor cells, thus solving the problem of limited efficacy of Devimistat due to its lack of targeting.

The invention relates to a medicine for improving expression of lysosome related transmembrane protein 4B and a screening method of the medicine, and belongs to the technical field of medicine screening. According to the invention, a fluorescent marker is accurately inserted into a target protein LAPTM4B gene locus, so that real-time monitoring of dynamic change of endogenous protein is realized; meanwhile, membrane protein CD63 is introduced as an internal reference signal, a high-throughput automatic drug screening and image analysis system is utilized to quantitatively screen compounds in a large-scale drug library, finally, drugs capable of improving LAPTM4B expression are screened out, and a new direction is provided for subsequent research on therapeutic targets related to lysosome-related transmembrane protein 4B. Meanwhile, the screened medicine is good in specificity, LAPTM4B expression can be improved, but CD63 is not affected, so that time-space precise control over LAPTM4B activity can be achieved, and the method has important significance in construction of an in-vitro / in-vivo instantaneous activation model.

The present invention relates to a drug delivery system with a micelle structure comprising a PEG2000-DSPE polymerized lipid and an APTEDB-PEG2000-DSPE polymer, and a preparation method thereof. The drug delivery system targets extra-domain B of fibronectin (EDB-FN), which is overexpressed in a brain tumor, and can pass through the blood-brain barrier (BBB) or the blood-brain tumor barrier (BBTB) to deliver a drug specifically to the brain tumor cells. In addition, the present invention can provide a pharmaceutical composition for diagnosing or treating a brain tumor, comprising the drug-loaded drug delivery system as an active ingredient. The composition can be accumulated inside the brain tumor and incorporated into the tumor cells to specifically inhibit tumor growth, and thus can be efficiently utilized for diagnosing or treating a brain tumor.

A polypeptide-oligonucleotide conjugate and use thereof. The polypeptide-oligonucleotide conjugate comprises (1) a polypeptide that binds to an LRP2 receptor, and (2) one or two oligonucleotide drugs for regulating the expression of a kidney target gene. The conjugate specifically delivers an siRNA drug to the kidney using the LRP2-targeting peptide.